Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
作者信息
Ferrero Simone, Dreyling Martin
机构信息
Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy.
Department of Medicine III, Hospital of the University LMU München, Germany
出版信息
Haematologica. 2017 Jul;102(7):1133-1136. doi: 10.3324/haematol.2017.167627.
Abstract
摘要
相似文献
1
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?套细胞淋巴瘤中的微小残留病：我们是否准备好采用个性化治疗方法？
Haematologica. 2017 Jul;102(7):1133-1136. doi: 10.3324/haematol.2017.167627.
2
Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.采用8色流式细胞术监测套细胞淋巴瘤微小残留病：一项欧盟-套细胞淋巴瘤和LYSA研究
Haematologica. 2016 Mar;101(3):336-45. doi: 10.3324/haematol.2015.134957. Epub 2015 Dec 24.
3
Optimal management of mantle cell lymphoma in the primary setting.原发部位套细胞淋巴瘤的最佳治疗策略。
Expert Rev Hematol. 2019 Sep;12(9):715-721. doi: 10.1080/17474086.2019.1639501. Epub 2019 Jul 19.
4
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?靶向治疗在套细胞淋巴瘤中的作用：移植是过时了还是仍有价值？
Haematologica. 2016 Feb;101(2):104-14. doi: 10.3324/haematol.2014.119115.
5
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.诱导免疫化疗后微小残留病的检测可预测套细胞淋巴瘤的无进展生存期：CALGB 59909 的最终结果。
Haematologica. 2012 Apr;97(4):579-85. doi: 10.3324/haematol.2011.050203. Epub 2011 Nov 18.
6
Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.精准医学时代的套细胞淋巴瘤——诊断、生物标志物与治疗药物
Oncotarget. 2016 Jul 26;7(30):48692-48731. doi: 10.18632/oncotarget.8961.
7
SOX11, CCND1, BCL1/IgH and IgH-VDJ: a battle of minimal residual disease markers in mantle cell lymphoma?SOX11、CCND1、BCL1/IgH和IgH-VDJ：套细胞淋巴瘤中微小残留病标志物的较量？
Leuk Lymphoma. 2015;56(9):2724-7. doi: 10.3109/10428194.2015.1004672. Epub 2015 Feb 11.
8
Clinical Management Updates in Mantle Cell Lymphoma.套细胞淋巴瘤的临床管理进展
Oncology (Williston Park). 2016 Apr;30(4):353-60.
9
[Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].[滤泡性和套细胞淋巴瘤中的微小残留病。通过循环淋巴瘤细胞的定量分子监测进行检测]
Dtsch Med Wochenschr. 2005 Sep 23;130(38):2130-4. doi: 10.1055/s-2005-916352.
10
Optimal frontline management of mantle cell lymphoma: can we agree?套细胞淋巴瘤的最佳一线治疗：我们能达成共识吗？
Expert Rev Hematol. 2018 Dec;11(12):911-914. doi: 10.1080/17474086.2018.1537778. Epub 2018 Nov 5.
引用本文的文献
1
Tackling Mantle Cell Lymphoma in Europe.欧洲应对套细胞淋巴瘤
Healthcare (Basel). 2022 Sep 3;10(9):1682. doi: 10.3390/healthcare10091682.
2
Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing.利用二代测序技术探索套细胞淋巴瘤干细胞产品中的残留病灶。
Leuk Res Rep. 2022 Aug 9;18:100341. doi: 10.1016/j.lrr.2022.100341. eCollection 2022.
3
Targeted Locus Amplification as Marker Screening Approach to Detect Immunoglobulin (IG) Translocations in B-Cell Non-Hodgkin Lymphomas.靶向基因扩增作为标记物筛选方法检测 B 细胞非霍奇金淋巴瘤中的免疫球蛋白（IG）易位。
Methods Mol Biol. 2022;2453:119-132. doi: 10.1007/978-1-0716-2115-8_8.
4
The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow.双重免疫组织化学染色在骨髓中检测套细胞淋巴瘤的有效性。
Am J Clin Pathol. 2022 May 4;157(5):709-717. doi: 10.1093/ajcp/aqab179.
5
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network.淋巴瘤中基于PCR的微小残留病质量评估：意大利淋巴瘤基金会微小残留病网络内10年的跨实验室标准化进程
Hemasphere. 2021 Sep 6;5(10):e639. doi: 10.1097/HS9.0000000000000639. eCollection 2021 Oct.
6
Advances in the assessment of minimal residual disease in mantle cell lymphoma.套细胞淋巴瘤微小残留病评估的研究进展。
J Hematol Oncol. 2020 Sep 24;13(1):127. doi: 10.1186/s13045-020-00961-8.
7
Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.新型口服药物时代的套细胞淋巴瘤的治疗管理。
Ann Pharmacother. 2020 Sep;54(9):879-898. doi: 10.1177/1060028020909117. Epub 2020 Feb 20.
8
Mantle Cell Lymphoma: Which Patients Should We Transplant?套细胞淋巴瘤：哪些患者适合进行移植？
Curr Hematol Malig Rep. 2019 Aug;14(4):239-246. doi: 10.1007/s11899-019-00520-0.
本文引用的文献
1
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.二线利妥昔单抗、来那度胺和苯达莫司汀治疗套细胞淋巴瘤：意大利淋巴瘤基金会的一项II期临床试验
Haematologica. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12.
2
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.自体干细胞移植及利妥昔单抗抢先治疗分子复发后的分子监测；北欧套细胞淋巴瘤研究（MCL2和MCL3）结果，中位随访8.5年
Biol Blood Marrow Transplant. 2017 Mar;23(3):428-435. doi: 10.1016/j.bbmt.2016.12.634. Epub 2016 Dec 27.
3
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.利妥昔单抗、苯达莫司汀和小剂量阿糖胞苷作为老年套细胞淋巴瘤患者的诱导治疗：来自意大利淋巴瘤基金会的一项多中心2期试验
Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.
4
Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing.通过下一代测序技术对淋巴增殖性疾病进行全面的易位和克隆性检测。
Haematologica. 2017 Feb;102(2):e57-e60. doi: 10.3324/haematol.2016.155424. Epub 2016 Oct 20.
5
Targeted Locus Amplification and Next-Generation Sequencing.靶向基因座扩增与新一代测序
Methods Mol Biol. 2017;1492:185-196. doi: 10.1007/978-1-4939-6442-0_13.
6
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.来那度胺-苯达莫司汀-利妥昔单抗治疗未经治疗的老年套细胞淋巴瘤患者。
Blood. 2016 Oct 6;128(14):1814-1820. doi: 10.1182/blood-2016-03-704023. Epub 2016 Jun 27.
7
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.在年龄为 65 岁或以下的套细胞淋巴瘤（MCL Younger）患者中，在自体干细胞移植前给予高剂量阿糖胞苷联合免疫化疗：欧洲套细胞淋巴瘤网络的一项随机、开放标签、3 期试验。
Lancet. 2016 Aug 6;388(10044):565-75. doi: 10.1016/S0140-6736(16)00739-X. Epub 2016 Jun 14.
8
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.利妥昔单抗-苯达莫司汀和利妥昔单抗-阿糖胞苷用于适合移植的套细胞淋巴瘤患者的2期研究。
Br J Haematol. 2016 Apr;173(1):89-95. doi: 10.1111/bjh.13929. Epub 2016 Jan 5.
9
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.通过液滴数字PCR检测多发性骨髓瘤、套细胞淋巴瘤和滤泡性淋巴瘤中的微小残留病：与实时PCR的比较
J Mol Diagn. 2015 Nov;17(6):652-60. doi: 10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28.
10
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.通过免疫球蛋白高通量测序对弥漫性大B细胞淋巴瘤进行无创监测。
Blood. 2015 Jun 11;125(24):3679-87. doi: 10.1182/blood-2015-03-635169. Epub 2015 Apr 17.
Zotero 插件